Telix Pharmaceuticals | TLX - PE Price to Earnings

Stock Price
13.90
Daily Change
0.30 2.21%
Monthly
-17.70%
Yearly
-23.42%
Q3 Forecast
13.73

Telix Pharmaceuticals reported AUD164.4 in PE Price to Earnings for its fiscal semester ending in June of 2024.



Financials
Stock Price AUD
Assets AUD 1.52B
Cash and Equivalent AUD 710.35M
Cost of Sales AUD 148.66M
Current Assets AUD 918.56M
Current Liabilities AUD 330.91M
Debt AUD 581.45M
EBIT AUD 37.44M
EBITDA AUD 33.24M
EPS Earnings Per Share AUD 0.28
Equity Capital and Reserves AUD 568.21M
Gross Profit on Sales AUD 129.12M
Interest Expense on Debt AUD 3.39M
Interest Income AUD 1.37M
Loan Capital AUD 551.82M
Market Capitalization AUD 4.41B
Net Income AUD 10.13M
Operating Expenses AUD 191.9M
Operating Profit AUD 17.72M
Ordinary Share Capital AUD 334.73M
PE Price to Earnings AUD 164.4
Pre-Tax Profit AUD 10.69M
Sales Revenues AUD 309.72M
Selling and Administration Expenses AUD 55.91M
Stock AUD 38.14M
Trade Creditors AUD 68.7M
Trade Debtors AUD 158.99M

Pe Change Date
Cochlear AUD 53.39 9.02 Jun/2024
CSL USD 32.13 6.47 Dec/2024
Integral Diagnostics AUD 17.93 19.06 Jun/2023
Medical Developments International AUD 1.17K 765.75 Jun/2020
Neuren Pharmaceuticals AUD 13.64 3.76 Jun/2024
Polynovo AUD 271.28 793.94 Jun/2024
Ramsay Health Care AUD 31.14 18.11 Jun/2024
ResMed USD 28.85 1.47 Jun/2025
Sonic Healthcare AUD 25.23 0.59 Jun/2024